Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kulke

Showing results (51-60 of 182) with videos related to

Pageof 19
Sort By:
Gastroenterology|July 29, 2008
Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growthKotoyo Fujiki, Eva-Maria Duerr, Hirotoshi Kikuchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumorsMatthew H Kulke, Keith Stuart, Peter C Enzinger, et al.
American Journal of Clinical Oncology|December 15, 2004
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumorsA David McCollum, Matthew H Kulke, David P Ryan, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2010
Phase II study of pemetrexed in patients with advanced neuroendocrine tumorsJennifer A Chan, Andrew X Zhu, Keith Stuart, et al.
Pancreas|February 9, 2021
Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 StudiesDavid L Chan, James C Yao, Carlo Carnaghi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2023
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinomaLaura Burns, Hanna Tukachinsky, Kira Raskina, et al.
Cancer|April 15, 2021
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trialsNicola Fazio, Carlo Carnaghi, Roberto Buzzoni, et al.
Clinical Therapeutics|November 28, 2018
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTARDavid Cella, Jennifer L Beaumont, Stacie Hudgens, et al.
Endocrine-Related Cancer|August 6, 2016
Genetic associations with neuroendocrine tumor risk: results from a genome-wide association studyYeting Du, Monica Ter-Minassian, Lauren Brais, et al.
Cancer|August 27, 2004
A Phase II trial of gemcitabine for metastatic neuroendocrine tumorsMatthew H Kulke, Haesook Kim, Jeffrey W Clark, et al.
Pageof 19

Showing results (51-60 of 182) with videos related to

Sort By:
Pageof 19
Gastroenterology|July 29, 2008
Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growthKotoyo Fujiki, Eva-Maria Duerr, Hirotoshi Kikuchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2006
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumorsMatthew H Kulke, Keith Stuart, Peter C Enzinger, et al.
American Journal of Clinical Oncology|December 15, 2004
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumorsA David McCollum, Matthew H Kulke, David P Ryan, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2010
Phase II study of pemetrexed in patients with advanced neuroendocrine tumorsJennifer A Chan, Andrew X Zhu, Keith Stuart, et al.
Pancreas|February 9, 2021
Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 StudiesDavid L Chan, James C Yao, Carlo Carnaghi, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2023
Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinomaLaura Burns, Hanna Tukachinsky, Kira Raskina, et al.
Cancer|April 15, 2021
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trialsNicola Fazio, Carlo Carnaghi, Roberto Buzzoni, et al.
Clinical Therapeutics|November 28, 2018
Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTARDavid Cella, Jennifer L Beaumont, Stacie Hudgens, et al.
Endocrine-Related Cancer|August 6, 2016
Genetic associations with neuroendocrine tumor risk: results from a genome-wide association studyYeting Du, Monica Ter-Minassian, Lauren Brais, et al.
Cancer|August 27, 2004
A Phase II trial of gemcitabine for metastatic neuroendocrine tumorsMatthew H Kulke, Haesook Kim, Jeffrey W Clark, et al.
Pageof 19